Fundraising Fox

Windtree Therapeutics INC /De

OTC: WINT

Warrington, US · Delaware corporation · 1 known investors

Biotech

Founders & leadership

MB
Mary B. TempletonExecutive
CE
Craig E. FraserExecutive
LA
Lawrence A. WeinsteinExecutive
KC
Kathryn ColeExecutive
JT
John TattoryExecutive
GC
George CoxExecutive
SS
Steven SimonsonExecutive
RC
Russell Clayton, D.O.Senior Vice President, Research and Development
ML
Michael L. MageeVice President, Quality Operations
JC
John C. CooperPresident and CEO
ME
Marvin E. Rosenthale, Ph.D.Named on SEC filing
TC
Thomas C. HoyVice President, Manufacturing Operations

Investors · 1

Agent CapitalreportedWalthamvia Bruce Peacock · board

Reported raises · per SEC filings

Form D private placements

$52.4M disclosed across 6 of 7 rounds · 2014–2019

▶$26.4MraisedDec 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James HuangDirector
  • Daniel GeffkenDirector
  • Craig FraserExecutive Officer, Director
  • John LeoneDirector
  • Mary B. TempletonExecutive Officer
  • Bruce PeacockDirector
  • Brian SchreiberDirector
  • Steven SimonsonExecutive Officer
  • John TattoryExecutive Officer
  • Joseph MahadyDirector
Offering amount
$26.4M
Amount sold
$26.4M
Sales commissions
$324K
Placement agents
Rui Jin (HK) Consulting Management Company Limited
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence A. WeinsteinExecutive Officer
  • Bruce A. PeacockDirector
  • Joseph M. MahadyDirector
  • John R. LeoneDirector
  • Brian SchreiberDirector
  • Craig E. FraserExecutive Officer, Director
  • Steven SimonsonExecutive Officer
  • George CoxExecutive Officer
  • Mary B. TempletonExecutive Officer
  • John TattoryExecutive Officer
  • James HuangDirector
  • Kathryn ColeExecutive Officer
Offering amount
$1M
Amount sold
$1M
First sale
Dec 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.6MraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce A. PeacockDirector
  • Marvin E. RosenthaleDirector
  • Steven A. SimonsonExecutive Officer
  • Craig E. FraserExecutive Officer, Director
  • John R. LeoneDirector
  • George CoxExecutive Officer
  • Kathryn ColeExecutive Officer
  • Lawrence A. WeinsteinExecutive Officer
  • Mary B. TempletonExecutive Officer
  • Joseph M. MahadyDirector
  • John TattoryExecutive Officer
Offering amount
$2.6M
Amount sold
$2.6M
First sale
Mar 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Marvin E. RosenthaleDirector
  • Joseph M. MahadyDirector
  • George CoxExecutive Officer
  • John TattoryExecutive Officer
  • Bruce A. PeacockDirector
  • Mary B. TempletonExecutive Officer
  • Craig E. FraserExecutive Officer, Director
  • Lawrence A. WeinsteinExecutive Officer
  • John R. LeoneDirector
  • Steven A. SimonsonExecutive Officer
  • Kathryn ColeExecutive Officer
Offering amount
$1.5M
Amount sold
$1.5M
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.3MraisedNov 2017 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mary B. TempletonExecutive Officer
  • Lawrence A. WeinsteinExecutive Officer
  • John TattoryExecutive Officer
  • Marvin E. RosenthaleDirector
  • George CoxExecutive Officer
  • Bruce A. PeacockDirector
  • Craig E. FraserExecutive Officer, Director
  • Kathryn ColeExecutive Officer
  • John R. LeoneDirector
  • Joseph M. MahadyDirector
  • Steven A. SimonsonExecutive Officer
Offering amount
$10.3M
Amount sold
$10.3M
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.5MraisedFeb 2017 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mary B. TempletonExecutive Officer
  • Craig E. FraserExecutive Officer, Director
  • Lawrence A. WeinsteinExecutive Officer
  • Kathryn ColeExecutive Officer
  • Marvin E. RosenthaleDirector
  • Joseph M. MahadyDirector
  • Bruce A. PeacockDirector
  • John R. LeoneDirector
  • John TattoryExecutive Officer
  • George CoxExecutive Officer
  • Steven A. SimonsonExecutive Officer
Offering amount
$10.5M
Amount sold
$10.5M
First sale
Feb 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.5MofferedOct 2014 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Russell Clayton, D.O.Executive Officer
  • Michael L. MageeExecutive Officer
  • John C. CooperExecutive Officer, Director
  • Marvin E. Rosenthale, Ph.D.Director
  • Thomas C. HoyExecutive Officer
  • John R. LeoneDirector
  • Mary B. Templeton, Esq.Executive Officer
  • Kathryn ColeExecutive Officer
  • John TattoryExecutive Officer
  • Bruce A. PeacockDirector
  • Thomas F. Miller, Ph.D., MBAExecutive Officer
  • Joseph M. MahadyDirector
Offering amount
$7.5M
First sale
Oct 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Windtree Therapeutics INC /De's investors?
Windtree Therapeutics INC /De's investors include Agent Capital.
How much funding has Windtree Therapeutics INC /De raised?
Windtree Therapeutics INC /De has disclosed $52.4M raised across 6 of its 7 known rounds.
Where is Windtree Therapeutics INC /De headquartered?
Windtree Therapeutics INC /De is headquartered in Warrington, US.